NO971764L - Levedyktige, forurensningspartikkelfrie adenoviruser, deres fremstilling og anvendelse - Google Patents

Levedyktige, forurensningspartikkelfrie adenoviruser, deres fremstilling og anvendelse

Info

Publication number
NO971764L
NO971764L NO971764A NO971764A NO971764L NO 971764 L NO971764 L NO 971764L NO 971764 A NO971764 A NO 971764A NO 971764 A NO971764 A NO 971764A NO 971764 L NO971764 L NO 971764L
Authority
NO
Norway
Prior art keywords
viable
pollution
preparation
adenoviruses
free
Prior art date
Application number
NO971764A
Other languages
English (en)
Other versions
NO320090B1 (no
NO971764D0 (no
Inventor
Patrice Yeh
Michel Perricaudet
Cecile Orsini
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO971764L publication Critical patent/NO971764L/no
Publication of NO971764D0 publication Critical patent/NO971764D0/no
Publication of NO320090B1 publication Critical patent/NO320090B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19971764A 1994-10-28 1997-04-17 Rekombinant adenovirus, dens fremstilling samt farmasoytisk preparat inneholdende virusen. NO320090B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9413355A FR2726285B1 (fr) 1994-10-28 1994-10-28 Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
PCT/FR1995/001415 WO1996013596A1 (fr) 1994-10-28 1995-10-25 Adenovirus depourvus de particules contaminantes viables, preparation et utilisations

Publications (3)

Publication Number Publication Date
NO971764L true NO971764L (no) 1997-04-17
NO971764D0 NO971764D0 (no) 1997-04-17
NO320090B1 NO320090B1 (no) 2005-10-24

Family

ID=9468601

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971764A NO320090B1 (no) 1994-10-28 1997-04-17 Rekombinant adenovirus, dens fremstilling samt farmasoytisk preparat inneholdende virusen.

Country Status (13)

Country Link
US (2) US6312946B1 (no)
EP (1) EP0787199A1 (no)
JP (1) JPH10507922A (no)
KR (1) KR100424803B1 (no)
CN (1) CN1110564C (no)
AU (1) AU703539B2 (no)
FI (1) FI971783A7 (no)
FR (1) FR2726285B1 (no)
IL (1) IL115779A0 (no)
MX (1) MX9702553A (no)
NO (1) NO320090B1 (no)
WO (1) WO1996013596A1 (no)
ZA (1) ZA959086B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE336587T1 (de) * 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
DE69534166T2 (de) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
WO1996018418A1 (en) * 1994-12-12 1996-06-20 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
FR2748753B1 (fr) * 1996-05-20 1998-08-14 Transgene Sa Nouveaux vecteurs adenoviraux pour la therapie genique
DE69725882T2 (de) * 1996-07-05 2004-07-29 Branton, Philip E., St. Lambert Adenovirus e4 proteine für induktion von zelltod
US6730662B1 (en) 1996-07-05 2004-05-04 Mcgill University Adenovirus E4 proteins for inducing cell death
WO1998010087A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
FR2755699B1 (fr) * 1996-11-08 1998-12-18 Rhone Poulenc Rorer Sa Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
WO1998049321A2 (en) 1997-04-28 1998-11-05 Rhone-Poulenc Rorer S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
ES2180258T3 (es) * 1998-07-07 2003-02-01 Transgene Sa Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
US6461869B1 (en) * 1999-07-20 2002-10-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Purging leukemia cells from hematopoietic stem cells
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
US7445929B2 (en) * 2000-05-26 2008-11-04 Dainippon Sumitomo Pharma Co., Ltd. Recombinant adenovirus vector having a reduced side effect
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
WO2006060089A2 (en) * 2004-10-25 2006-06-08 Biogen Idec Ma Inc. Novel methods for producing adenoviral vector preparations with reduced replication-competent adenovirus contamination and novel adenoviral vectors and preparations
SG173414A1 (en) 2006-07-28 2011-08-29 Sanofi Aventis Fr Composition and method for treatment of tumors
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
BR112013003579A2 (pt) * 2010-08-16 2016-06-07 Salk Inst For Biological Studi adenovírus, células, e, métodos para tratar câncer
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
US12098384B2 (en) 2021-01-21 2024-09-24 Cellid Co., Ltd. Adenoviral vector not including replication competent adenovirus, and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy

Also Published As

Publication number Publication date
FR2726285B1 (fr) 1996-11-29
KR100424803B1 (ko) 2004-06-12
FI971783L (fi) 1997-04-25
WO1996013596A1 (fr) 1996-05-09
AU703539B2 (en) 1999-03-25
US6312946B1 (en) 2001-11-06
AU3847795A (en) 1996-05-23
CN1162338A (zh) 1997-10-15
NO320090B1 (no) 2005-10-24
EP0787199A1 (fr) 1997-08-06
KR970707292A (ko) 1997-12-01
IL115779A0 (en) 1996-01-19
FI971783A0 (fi) 1997-04-25
JPH10507922A (ja) 1998-08-04
CN1110564C (zh) 2003-06-04
NO971764D0 (no) 1997-04-17
US6482617B2 (en) 2002-11-19
ZA959086B (en) 1996-07-16
MX9702553A (es) 1997-06-28
FR2726285A1 (fr) 1996-05-03
FI971783A7 (fi) 1997-04-25
US20010039046A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
NO971764L (no) Levedyktige, forurensningspartikkelfrie adenoviruser, deres fremstilling og anvendelse
NO954369L (no) Oksazolidindionderivater, deres fremstilling og anvendelse
NO933434D0 (no) Piperidinderivater, deres fremstilling og anvendelse
NO912058D0 (no) Bioforlikelige membraner, deres fremstilling og anvendelse
DK374389D0 (da) Arylbenzenoxazolidinoner, deres fremstilling og anvendelse
DK1019358T3 (da) 3,3-diarylpropylaminer, deres anvendelse og fremstilling
NO964306D0 (no) Ligninblanding, fremstilling og anvendelse derav
DK0871656T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
NO943682D0 (no) Imidazol-4-yl-piperidin-derivater, deres fremstilling og terapeutiske anvendelse
NO951447D0 (no) Organoaluminoksyprodukt, fremstilling og anvendelse
NO953673D0 (no) [1,2,4ÅTriazolo[4,3-aÅkinoksalinderivater, deres fremstilling og anvendelse
DK388989A (da) Acylcyanoguanidiner, deres fremstilling og anvendelse
DK0690065T3 (da) Biphenyl-2,2'-diyl-bis-diphenylphosphiner, deres fremstilling og deres anvendelse
DK435289A (da) Piperazindioner, deres fremstilling og anvendelse
NO951418D0 (no) Peptidderivater, deres fremstilling og anvendelse som terapeutika
DK60893D0 (da) Piperidinderivater, deres fremstilling og anvendelse
NO933435D0 (no) Piperidinderivater, deres fremstilling og anvendelse
DK73091D0 (da) Quinoxalinforbindelser, deres fremstilling og anvendelse
DK225089D0 (da) 2-adamantyl-4-isothiazolin-3-oner, deres fremstilling og anvendelse
NO922992L (no) Imid-terminerte polynitrogenforbindelser, deres fremstilling og anvendelse
NO972821D0 (no) 1-C-perfluoralkylglycosider, deres fremstilling og anvendelse
FI965172A7 (fi) Uusia amido-kinoksaliinidioneja, niiden valmistus ja käyttö
NO996156L (no) Substituerte cykloheptener, deres fremstilling og anvendelse
NO951812D0 (no) Pyrrolderivater, deres fremstilling og anvendelse
DK592389D0 (da) Penemderivater, deres fremstilling og anvendelse